Breaking News Instant updates and real-time market news.

DVAX

Dynavax

$5.60

0.05 (0.90%)

, MRK

Merck

$63.89

0.89 (1.41%)

06:03
05/19/17
05/19
06:03
05/19/17
06:03

Dynavax to present data on SD-101 in combination with KEYTRUDA at ASCO

Dynavax (DVAX) announced that updated data from an ongoing Phase 1b/2 study investigating SD-101, Dynavax's intratumoral TLR9 agonist, in combination with KEYTRUDA, an anti-PD-1 therapy developed by Merck (MRK), will be presented in a poster at the 2017 American Society of Clinical Oncology Annual Meeting. The poster presentation will include updated data from those in the abstract.

DVAX

Dynavax

$5.60

0.05 (0.90%)

MRK

Merck

$63.89

0.89 (1.41%)

  • 23

    May

  • 27

    May

  • 31

    May

  • 02

    Jun

  • 05

    Jun

  • 09

    Jun

  • 14

    Jun

  • 28

    Jul

  • 10

    Aug

DVAX Dynavax
$5.60

0.05 (0.90%)

11/15/16
WBLR
11/15/16
NO CHANGE
Target $17
WBLR
Outperform
William Blair still sees 'good chance' for approval of Dynavax's Heplisav
William Blair analyst Y. Katherine Xu lowered her price target for Dynavax Technologies to $17 from $45 after the company received a second Complete Response Letter from the FDA for the Heplisav Biologics License Application. There is still a "good chance" for Heplisav to garner eventual approval, Xu tells investors in a research note. The lack of apparent concerns regarding rare serious autoimmune events is a plus, the analyst contends. Xu keeps an Outperform rating on Dynavax. She points out the company's immuno-oncology program SD-101 is reading out substantial data starting in 2017. Dynavax closed yesterday down 65% to $4.10.
11/14/16
COWN
11/14/16
NO CHANGE
Target $45
COWN
Outperform
Dynavax's Heplisav may still have a path forward, says Cowen
Cowen analyst Phil Nadeau called the CRL issued to Dynavax regarding its Biologics License Application for Heplisav-B "disappointing and concerning," but also noted that the FDA did not request new trials. While the CRL will push approval until late 2017, in a best case scenario, there may still be a path forward for approval of the drug, said Nadeau, who added that he thinks the stock now looks undervalued. The analyst has an Outperform rating and $45 price target on Dynavax shares.
09/06/16
WBLR
09/06/16
NO CHANGE
WBLR
Outperform
FDA panel cancelation positive for Dynavax, says William Blair
William Blair analyst Y. Katherine Xu views the FDA's decision to canceled the November 16 Vaccines and Related Biological Products Advisory Committee meeting for Heplisav as a net positive for Dynavax. The agency's decision to move straight to the PDUFA date suggests that the Heplisav package is "sufficiently strong and adequate to warrant approval in the absence of a panel," Xu tells investors in a research note. She keeps an Outperform rating on Dynavax. The stock is up 19% to $13.00 in pre-market trading.
MRK Merck
$63.89

0.89 (1.41%)

05/11/17
BMOC
05/11/17
NO CHANGE
BMOC
Merck Keytruda approval positive, says BMO Capital
BMO Capital analyst Alex Arfaei notes that the FDA approved Keytruda + chemo in first line NSCLC. The analyst says that the label is "solid," and he expects "strong uptake" for the drug in the condition, based on his checks with oncologists. The analyst raised his price target on the shares to $74 from $71 and keeps an Outperform rating on the stock.
05/03/17
BMOC
05/03/17
NO CHANGE
BMOC
Merck results more positive than first appeared, says BMO Capital
BMO Capital analyst Alex Arfaei says he's more upbeat on Merck's Q1 results following its conference call. He says that the lower than expected Januvia revenue is "explainable," while the company's Keytruda drug looks set to beat expectations in 2H17. The analyst expects the company's 2017 results to come in at the top half of its guidance range, and he thinks the stock can rise, driven by Keytruda and its hepatitis C treatments. The analyst keeps an Outperform rating on the shares.
04/20/17
JEFF
04/20/17
NO CHANGE
Target $51
JEFF
Underperform
Jefferies lowers Merck estimates, drops target to $51
Jefferies analyst Jeffrey Holford lowered his earnings estimates for Merck by up to 3% citing concerns on pricing for Januvia/Janumet. The analyst notes that his mid-term estimates are now up to 11% below consensus. Holford expects Keytruda, Januvia and Gardasil to miss expectations Q1. He cut his price target for Merck to $51 from $52 and keeps an Underperform rating on the name.
04/04/17
STFL
04/04/17
NO CHANGE
STFL
NewLink Genetics should be bought on weakness after data, says Stifel
Stifel analyst Stephen Willey said NewLink Genetics' (NLNK) combination of indoximod and Merck's (MRK) pembrolizumab in patients with treatment-naive melanoma demonstrated an overall response rate, or ORR, that is "essentially identical" to the previously-reported results from the Incyte (INCY)-Merck study of epacadostat/pembrolizumab. The lower rate of complete responses he doesn't "find terribly surprising" given what is already known about the current indoximod formulation, he tells investors. Willey, who views today's weakness as an interesting buying opportunity ahead of P1/2 data on the atezolizumab + GDC-0919 combination, keeps a Buy rating on Newlink shares.

TODAY'S FREE FLY STORIES

AZO

AutoZone

$659.49

-14.16 (-2.10%)

, MOMO

Momo

$42.83

-0.75 (-1.72%)

20:25
05/22/17
05/22
20:25
05/22/17
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

AZO

AutoZone

$659.49

-14.16 (-2.10%)

MOMO

Momo

$42.83

-0.75 (-1.72%)

TTWO

Take-Two

$69.04

1.46 (2.16%)

TOL

Toll Brothers

$38.03

0.19 (0.50%)

CBRL

Cracker Barrel

$161.41

2.41 (1.52%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

  • 23

    May

  • 23

    May

  • 23

    May

  • 23

    May

  • 25

    May

  • 29

    Jun

TWX

Time Warner

$97.90

0.27 (0.28%)

, DIS

Disney

$107.63

0.11 (0.10%)

20:07
05/22/17
05/22
20:07
05/22/17
20:07
Periodicals
Zack Snyder steps away from 'Justice League,' Hollywood Reporter says »

Zack Snyder, director of…

TWX

Time Warner

$97.90

0.27 (0.28%)

DIS

Disney

$107.63

0.11 (0.10%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Jun

OMN

Omnova Solutions

$8.90

0.15 (1.71%)

19:54
05/22/17
05/22
19:54
05/22/17
19:54
Conference/Events
Omnova Solutions management to meet with Jefferies »

Meeting to be held in the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    May

19:52
05/22/17
05/22
19:52
05/22/17
19:52
General news
Breaking General news story  »

U.K. police says…

UHAL

Amerco

$384.37

5.63 (1.49%)

19:40
05/22/17
05/22
19:40
05/22/17
19:40
Hot Stocks
U-Haul acquires portable storage containers of Door To Door »

Amerco's U-Haul…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    May

AAPL

Apple

$153.99

0.93 (0.61%)

19:34
05/22/17
05/22
19:34
05/22/17
19:34
Periodicals
Apple launches new Android 'switching' site, ads, AppleInsider says »

Apple has launched an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Jun

AMZN

Amazon.com

$970.67

10.83 (1.13%)

19:34
05/22/17
05/22
19:34
05/22/17
19:34
Periodicals
Amazon plans to offer live TV channels in Europe, FT reports »

Amazon plans to offer…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

TWTR

Twitter

$18.43

0.08 (0.44%)

19:30
05/22/17
05/22
19:30
05/22/17
19:30
Hot Stocks
Twitter hires Todd Swidler as global head of live business »

Twitter COO and CFO…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

  • 24

    May

TKPYY

Takeda Pharmaceutical Co. Ltd.

$25.87

0.025 (0.10%)

19:29
05/22/17
05/22
19:29
05/22/17
19:29
Conference/Events
Takeda Pharmaceutical Co. Ltd. management to meet with JPMorgan »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    May

GE

General Electric

$28.18

0.13 (0.46%)

19:27
05/22/17
05/22
19:27
05/22/17
19:27
Periodicals
EU examines potential misleading information in GE merger review, Bloomberg says »

The European Commission…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

  • 31

    May

  • 22

    Jun

  • 02

    Oct

GOOG

Alphabet

$941.86

7.85 (0.84%)

, GOOGL

Alphabet Class A

$964.07

9.42 (0.99%)

19:20
05/22/17
05/22
19:20
05/22/17
19:20
Periodicals
Alphabet's Nest working on 4K home security camera, AndroidPolice says »

Alphabet's Nest is…

GOOG

Alphabet

$941.86

7.85 (0.84%)

GOOGL

Alphabet Class A

$964.07

9.42 (0.99%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

  • 22

    May

  • 24

    May

CRM

Salesforce

$88.94

1.54 (1.76%)

19:19
05/22/17
05/22
19:19
05/22/17
19:19
Conference/Events
Salesforce management to meet with JPMorgan »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

  • 25

    May

  • 08

    Jun

19:15
05/22/17
05/22
19:15
05/22/17
19:15
General news
Breaking General news story  »

Federal Reserve Governor…

GE

General Electric

$28.18

0.13 (0.46%)

19:13
05/22/17
05/22
19:13
05/22/17
19:13
Periodicals
Aerion in talks with GE to power faster jets, Bloomberg reports »

Aerion Corporation is in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

  • 31

    May

  • 22

    Jun

  • 02

    Oct

BTU

Peabody Energy

$23.29

-0.01 (-0.04%)

19:13
05/22/17
05/22
19:13
05/22/17
19:13
Conference/Events
Peabody Energy management to meet with JPMorgan »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    May

  • 26

    May

AAPL

Apple

$153.99

0.93 (0.61%)

19:09
05/22/17
05/22
19:09
05/22/17
19:09
Periodicals
Apple Music trial implements small fee in some countries, AppleInsider says »

Apple has started…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Jun

TTWO

Take-Two

$69.04

1.46 (2.16%)

19:09
05/22/17
05/22
19:09
05/22/17
19:09
Recommendations
Take-Two analyst commentary at Piper Jaffray »

Take-Two delay of Red…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

  • 25

    May

BA

Boeing

$183.67

2.91 (1.61%)

, BDRBF

Bombardier

$1.57

0.0197 (1.27%)

19:06
05/22/17
05/22
19:06
05/22/17
19:06
Periodicals
Boeing fight against Bombardier driven by missteps with Airbus, Reuters says »

Boeing's (BA) recent…

BA

Boeing

$183.67

2.91 (1.61%)

BDRBF

Bombardier

$1.57

0.0197 (1.27%)

EADSY

Airbus

$20.38

-0.23 (-1.12%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    May

MTSC

MTS Systems

$53.80

0.45 (0.84%)

19:05
05/22/17
05/22
19:05
05/22/17
19:05
Conference/Events
MTS Systems management to meet with JPMorgan »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    May

  • 01

    Jun

HP

Helmerich & Payne

$59.88

-0.16 (-0.27%)

, HAL

Halliburton

$47.12

-0.66 (-1.38%)

19:04
05/22/17
05/22
19:04
05/22/17
19:04
Downgrade
Helmerich & Payne, Halliburton, ProPetro Holding, U.S. Silica rating change at Goldman Sachs »

Helmerich & Payne…

HP

Helmerich & Payne

$59.88

-0.16 (-0.27%)

HAL

Halliburton

$47.12

-0.66 (-1.38%)

PUMP

ProPetro Holding

$13.59

-0.14 (-1.02%)

SLCA

U.S. Silica

$38.77

-1.65 (-4.08%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

  • 20

    Jun

  • 24

    Jul

INVH

Invitation Homes

$21.67

-0.11 (-0.51%)

19:00
05/22/17
05/22
19:00
05/22/17
19:00
Conference/Events
Invitation Homes management to meet with JPMorgan »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    May

ATW

Atwood Oceanics

$8.73

0.03 (0.34%)

18:59
05/22/17
05/22
18:59
05/22/17
18:59
Upgrade
Atwood Oceanics rating change at Goldman Sachs »

Atwood Oceanics upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSLA

Tesla

$310.35

-0.48 (-0.15%)

18:56
05/22/17
05/22
18:56
05/22/17
18:56
Periodicals
Tesla confirms less than 100 configurations for Model 3, Electrek says »

Tesla confirmed today…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    May

  • 02

    Oct

EXPGY

Experian

$21.43

0.125 (0.59%)

18:56
05/22/17
05/22
18:56
05/22/17
18:56
Conference/Events
Experian management to meet with JPMorgan »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    May

  • 25

    May

18:55
05/22/17
05/22
18:55
05/22/17
18:55
Conference/Events
Federal Reserve Governor delivers dinner keynote speech »

Federal Reserve Governor…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.